AKAP9 regulation of microtubule dynamics promotes Epac1-induced endothelial barrier properties

*Seema Sehrawat,1 *Thomas Ernandez,1 Xavier Cullere,1 Mikiko Takahashi,2 Yoshitaka Ono,2 Yulia Komarova,3 and Tanya N. Mayadas1

1Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; 2Biosignal Research Center, Kobe University, Kobe, Japan; and 3Department of Pharmacology and Center for Lung and Vascular Biology, University of Illinois College of Medicine, Chicago, IL

Adhesive forces at endothelial cell-cell borders maintain vascular integrity. cAMP enhances barrier properties and controls cellular processes through protein kinase A bound to A-kinase anchoring proteins (AKAPs). It also activates exchange protein directly activated by cAMP (Epac1), an exchange factor for Ras-related protein 1 (Rap) GTPases that promotes cadherin- and integrin-mediated adhesion through effects on the actin cytoskeleton. We demonstrate that AKAP9 facilitates the microtubule polymerization rate in endothelial cells, interacts with Epac1, and is required for Epac1-stimulated microtubule growth. AKAP9 is not required for maintaining barrier properties under steady-state conditions. Rather, it is essential when the cell is challenged to make new adhesive contacts, as is the case when Epac activation enhances barrier function through a mechanism that, surprisingly, requires integrin adhesion at cell-cell contacts. In the present study, defects in Epac-induced responses in AKAP9-silenced cells were evident despite an intact Epac-induced increase in Rap activation, cortical actin, and vascular endothelial-cadherin adhesion. We describe a pathway that integrates Epac-mediated signals with AKAP9-dependent microtubule dynamics to coordinate integrins at lateral borders. (Blood. 2011;117(2): 708-718)

Introduction

Adherens junctions (AJs) at endothelial cell-cell contacts regulate the barrier properties of the endothelium by controlling the infiltration of plasma components and cells into the tissue. They undergo continuous remodeling in resting monolayers and in response to agents that alter permeability. These events are primarily coordinated by vascular endothelial (VE) cadherin and its associated cytoplasmic proteins, cytoskeletal-based contractile forces, and small GTPases.1 Endothelial integrins promote cell adhesion, spreading, migration, and survival, and, in concert with AJs, also contribute to barrier integrity.2,3 Although well known to bind at the cell-matrix interface, integrins also localize to endothelial junctions, where they may regulate barrier properties.4

cAMP is a well-known secondary messenger that enhances barrier properties, and its principal target is protein kinase A (PKA), which increases barrier function by reducing actomyosin contractility.2 PKA interacts with A-kinase anchoring proteins (AKAPs), a family of scaffolding proteins that reside in certain subcellular sites to spatially and temporally compartmentalize cAMP signaling.5 In addition, cAMP activates exchange protein directly activated by cAMP (Epac) proteins, which are guanine exchange factors for Ras-related protein 1 (Rap) GTPases that, in limited cases, transduce their signals by interacting with AKAP complexes.6,7 Epacs regulate several cellular functions, ranging from cell-cell and cell-matrix interactions, exocytosis, and cellular Ca2+ handling to gene expression.8 In endothelial cells (ECs), Epac1 activation enhances barrier function by increasing VE-cadherin adhesion and cortical actin, and opposes the effects of edemagenic agents and Rho GTPase activation.8 Recent work suggests that Epac interacts with microtubules (MTs) and the microtubule binding protein MAP1A,9,10 and enhances microtubule growth in ECs.11

Many aspects of cell-cell and cell-matrix adhesion require reorganization of actin and MTs at cortical sites. In contrast to the well-described relationship between cadherins and integrins with the actin cytoskeleton, the role of MTs in regulating these complexes is only beginning to be elucidated.12 MTs are highly dynamic structures. Commonly, the minus ends of MTs anchor at the centrosome and Golgi, while the plus ends establish transient interactions with sites of cell-to-cell and focal adhesions. This facilitates the delivery of cargo to maintain a gradient of AJ components and induces the turnover of focal adhesions. Microtubule dynamics, microtubule linkage to actin, and their capture at cortical sites are regulated by plus-end-binding proteins (+TIPs) such as EB1, CLIP-170, and CLASPs, which transiently bind to the plus ends of growing MTs.13 There is evidence that AKAP9 participates in microtubule remodeling. AKAP9 exists as both long isoforms and a short isoform called Yotiao.14 The long isoforms (350-450 kDa) localize to the centrosome and Golgi in interphase cells and promote microtubule regrowth,15 and recent studies have shown that they confer microtubule nucleating activity at the Golgi.16 However, the contribution of AKAP9 to the regulation of microtubule dynamics is not well understood, and the biological


*S.S. and T.E. contributed equally to this study.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

© 2011 by The American Society of Hematology
role of these large isoforms in cellular responses remains largely unexplored. We tested the hypothesis that AKAP9 and Epac1 interact functionally to enhance the barrier properties of the endothelium through effects on microtubule dynamics.

### Methods

#### Antibodies and reagents

Rabbit anti-AKAP9 was a gift from Drs Lei Chen and Robert Kass (Columbia University, New York, NY); anti-dynein light chain 1 was a gift from Kerry S. Campbell (Fox Chase Cancer Center, Philadelphia, PA); and anti-Glu tubulin was a gift from Dr G. G. Gunderson (Columbia University). Antibodies obtained from commercial sources were: VE-cadherin (Beckman Coulter); EB1 and GM130 (BD Biosciences); anti-Glu tubulin (Abcam); integrin αβ, (CD51/61) and αβ (CD94/CE chemicon); Yotiao (Invitrogen); platelet-endothelial cell adhesion molecule-1 (PECAM-1), β-catenin, and p-120 (BD Biosciences); Rap1 (Santa Cruz Biotechnology); flag (mouse monoclonal, clone M2), α-tubulin, V5, and β-actin (Sigma-Aldrich); pericentrin (Covance); and Epac1 (Cell Signaling Technology).

The reagents fibronectin, collagen type IV, phalloidin, nocodazole, RGD (Arg-Gly-Asp), RGE (Arg-Gly-Glu) peptide, and 4,6-diamidino-2-phenylindole (DAPI) were from Sigma-Aldrich; hVE-cadherin-Fc was provided by Dr Xiaodong Cheng (University of Texas, Galveston, TX).

#### Plasmid and virus production

Green fluorescent protein (GFP)–end-binding protein 1 (EB1) cDNA was used to generate adenovirus using the ViraPower Adenoviral Expression System (Invitrogen). Flag-AKAP9, AKAP9, AKAP9, and AKAP9 were as described previously, and empty CMV-3Xflag14 vector was from Sigma-Aldrich. The Epac1-V5 and the Epac1-flag constructs were generated by PCR using the Epac1-YFP cDNA vector provided by Dr Xiaodong Cheng (University of Texas, Galveston, TX).

#### Cell culture, RNA interference, and gene delivery

Human umbilical vein endothelial cells (HUVECs) were isolated and cultured on fibronectin-coated dishes. All endothelial experiments were conducted on HUVECs except where indicated. Human dermal microvascular endothelial cells (HDMECs) were a kind gift from Dr A. Kowalczyk (Emory University, Atlanta, GA). Cells were seeded onto fibronectin (5 μg/mL)–coated glass coverslips for immunofluorescence studies, and onto fibronectin (5 μg/mL) or collagen (0.8 mg/mL) gold-coated microtubule length (in micrometers) versus time (in seconds). Instantaneous velocities were calculated as displacement of the plus end between successive images (every 3 seconds) in a time-lapse series. The cell margin was defined as the 3-μm zone from the cell boundary. For live cell imaging, HUVECs were cultured on FN-coated glass-bottom MatTek plates (MatTek Corp) in M199 HVEC medium without phenol red, the media was covered with mineral oil, and cells were imaged at 37°C. Confocal images were obtained with an Olympus BX50WI microscope with a 60× objective. The acquisition and analysis software was MetaMorph (Molecular Devices). Immunohistochemistry was performed on OCT-embedded human skin sections using a 2-layer peroxidase method. Samples were stained with anti-Yotiao (also recognizing AKAP350/450) and anti–PECAM-1 and counterstained with Gill Hematoxylin No. 2 ( Fisher). Images were taken on a Nikon Microphot-FXA using a 10× objective.

#### Analysis of microtubule dynamics

The following parameters of microtubule dynamics were determined: instantaneous rates of growth, growth length, number of growing microtubule ends along the cell radius, and frequency of catastrophe events, as described previously. Briefly, live cell images were collected every 3 seconds for 50-60 frames. Data analysis was performed on 16-bit images using MetaMorph software. The length of growth from the centrosome was measured for individual MTs, and the life histories of MTs were plotted as length (in micrometers) versus time (in seconds). Instantaneous velocities were calculated as displacement of the plus end between successive images (every 3 seconds) in a time-lapse series. The cell margin was defined as the 3-μm zone from the cell boundary. For catastrophe frequencies, the number of microtubule catastrophe events over time of observation was determined.

Distribution of microtubule growing ends along the cell radius was determined by scoring the number of EB1 comets in 5 equal zones.

#### Western blotting, immunoprecipitation, and Rap pull-down assays

SDS-PAGE and immunoblotting with primary antibodies were done using standard protocols. Rap pull-down assays were performed as described previously. For Epac1-AKAP9 communoprecipitation assays, HEK 293T cells were cotransfected with Epac1-V5 and the flag-AKAP9 fragments and lysed after 48 hours in 1% NP-40, 50mM Tris-Cl (pH 8.0), 150mM NaCl buffer containing a protease inhibitor cocktail (Sigma-Aldrich). The cell lysates were precleared with protein-G Sepharose beads and incubated with protein-G Sepharose beads bound to either anti-flag or mouse immunoglobulin G (IgG). Immunoprecipitates were subjected to SDS-PAGE and immunoblotted with anti-V5 or anti-flag antibody to detect Epac1 or AKAP9, respectively.
30 minutes at 30,000 g containing 20% sucrose, 0.5 mM GTP and 10 μM taxol, and centrifuged for polymerization. Lysates were overlaid on a cushion of lysis buffer cell lysates were incubated for 20 minutes on ice to prevent microtubule/H9262 taxol (Sigma-Aldrich). As negative controls, aliquots of the same incubated for 20 minutes at 37°C after the addition of 0.5 mM GTP and 100 μg/mL, 70-kDa molecular mass; Invitrogen) in Hanks balanced salt solution without phenol red was added to the top chamber, and the bottom chamber was replaced with Hanks solution 15 minutes before the end of the time point. Fluorescence in the bottom chamber was read on a microplate reader (SpectraMax M2; Molecular Devices) after 15 minutes at 37°C.

**Flow cytometric analysis**

HUVEC monolayers were stained for 20 minutes at 37°C with anti-integrin antibodies (β1, α5, and αv) or the appropriate mouse IgG, and then rapidly trypsinized and resuspended in ice-cold PBS with 2% FCS. A donkey anti-mouse IgG Alexa-488-conjugated antibody (Invitrogen) was subsequently used and flow cytometric analysis was performed with a FACSCalibur (Becton Dickinson).

**Microtubule cosedimentation assay**

Microtubule cosedimentation was performed as described previously21 with some minor modifications. Cotransfected HEK 293T cells with Epac1-FLAG and flag-AKAP9p275-389p plasmids were lysed 48 hours after transfection, in PEM buffer (100 mM PIPES, pH 6.9, 1 mM EGTA, 1 mM MgCl2) with 1% Triton X-100 containing a protease inhibitor cocktail (Sigma-Aldrich). After 30 minutes of incubation on ice to depolymerize MTs, cell lysates were centrifuged at 100,000 g for 30 minutes at 4°C. Cleared lysates were incubated for 20 minutes at 37°C after the addition of 0.5 mM GTP and 20 μM taxol (Sigma-Aldrich). As negative controls, aliquots of the same cell lysates were incubated for 20 minutes on ice to prevent microtubule polymerization. Lysates were overlaid on a cushion of lysis buffer containing 20% sucrose, 0.5 mM GTP and 10 μM taxol, and centrifuged for 30 minutes at 30,000 g at 25°C to sediment MTs. Microtubule pellets were washed and resuspended in Laemmli loading buffer. Samples were separated by SDS-PAGE and immunoblotted with an anti-Epac1 antibody.

**Measurement of endothelial transelectrical resistance and dextran leakage**

Transelectrical resistance (TER) across the endothelial cell monolayer was measured using an impedance sensor system (Applied Biophysics). Data were normalized as the ratio of measured resistance to baseline resistance measured using an impedance sensor system. Data were plotted versus time. For integrin blocking experiments, cells were pretreated with α5 and αv specific antibodies or 800 μM RGD or RGE for 1 hour before the addition of O-Me-cAMP.

HUVECs were plated on 0.1% gelatin-coated transwell inserts (Costar), and 48 hours later the monolayers were treated with agonists for the indicated time points. Fluorescein-dextran (500 μg/mL, 70-kDa molecular mass; Invitrogen) in Hanks balanced salt solution without phenol red was added to the top chamber, and the bottom chamber was replaced with Hanks solution 15 minutes before the end of the time point. Fluorescence in the bottom chamber was read on a microplate reader (SpectraMax M2; Molecular Devices) after 15 minutes at 37°C.

**Figure 1. Analysis of AKAP9 350/450 expression in human ECs and characterization of cell cycle in AKAP9-depleted cells.** (A) Left panel, Western blotting (WB) of AKAP9 in HUVEC lysate and 293 cells transfected with Yotiao (293-Yotiao). A single band at the predicted molecular weight for AKAP350/450 long isoform(s) (arrow) was observed in HUVECs. The lower 250-kDa immunoreactive band in HUVECs did not migrate at the position of recombinant Yotiao in 293 cells (arrowhead). Right panel, qRT-PCR of HUVECs using primers that recognize the long isoforms (350/450 isoforms) or Yotiao was undertaken and their relative abundance (percentage of total AKAP9) was calculated. n = 4. (B) Confocal analysis of HUVECs stained with antibodies to the indicated proteins and DAPI (nucleus stain) followed by overlay of the images. AKAP9 (Akp9) codistributed with γ-tubulin, a centrosomal marker (top panel, arrow), and colocalized with GM-130, a cis-Golgi marker that is perinuclear and excludes the centrosome (bottom panel, arrow). Bar = 10 μm. (C) Tissue sections of human skin were stained with rabbit anti-Akp9, anti–PECAM-1 or rabbit IgG. AKAP9 was present in the large and small vessels (arrow) of the skin in a pattern coincident with an endothelial cell marker, PECAM-1, and in the epithelium. No specific staining was observed with IgG. (D) HUVECs were transfected with AKAP9 (Akp9) or Control (Con) siRNA duplexes (si), and evaluated 48 hours later for AKAP9 expression. Left panel, AKAP9 protein level was assessed by Western blotting. The lower 250-kDa protein remained upon AKAP9 silencing, suggesting that it is a nonspecific, immunoreactive band. Middle panel, AKAP9 message was quantified by qRT-PCR using oligonucleotides for long isoforms 350/450 kDa. Right panel, AKAP9 protein was assessed by immunofluorescence staining. (E) Representative cell-cycle profiles by fluorescence-activated cell sorting analysis of DNA content. Top left panel, AKAP9 silencing does not alter the distribution of cells in the different phases of the cell-cycle compared with control siRNA cells. Bottom left panel, an overlay of AKAP9 protein was assessed by immunofluorescence staining. Bar = 10 μm. (F) Top panel, AKAP9 silencing does not alter the distribution of cells in the different phases of the cell-cycle compared with control siRNA cells. Bottom left panel, an overlay of AKAP9 protein was assessed by immunofluorescence staining. Bar = 10 μm. (G) Top panel, AKAP9 silencing does not alter the distribution of cells in the different phases of the cell-cycle compared with control siRNA cells. Bottom left panel, an overlay of AKAP9 protein was assessed by immunofluorescence staining. Bar = 10 μm.
Ca\textsuperscript{2+} switch assay

HUVECs were cultured for 6 hours in low-Ca\textsuperscript{2+} medium (Eagle minimal essential medium), followed by restoration of extracellular Ca\textsuperscript{2+} by incubation with Eagle medium containing 1.8nM Ca\textsuperscript{2+}. After 1 hour, the cells were immunostained with VE-cadherin, p120-\textgreek{catenin}, or dynein antibody. Images were obtained and used to calculate the intensity of immunostaining at the junctions using the line scan method from MetaMorph. In this method, a line is drawn across the diameter of several cells, and the peak of fluorescence intensity, which represents the junctions, is averaged.

RGD and VE-cadherin adhesion assay

Cells were trypsinized and plated onto tissue culture plates coated with RGD and VE-cadherin adhesion assay averaged. and the peak of fluorescence intensity, which represents the junctions, is immunostaining at the junctions using the line scan method from Meta-

Statistical analysis

All data are presented as mean \( \pm \) SD except microtubule instantaneous growth rate and length of uninterrupted growth, for which median values are given. Two-sided paired \( t \) test or Wilcoxon paired rank test (for median values) were performed where appropriate. \( P < .05 \) was considered significant.

Results

Endothelial cells express the AKAP9 long isoforms and their silencing has no effect on cell division

AKAP9 protein expression was evaluated using an antibody that detects both the long AKAP9 and the Yotiao isoforms.\textsuperscript{27} Western blot analysis of HUVECs revealed a 400-kD AKAP9 species, while the 220-kD Yotiao was not observed (Figure 1A). Quantitative reverse transcriptase-PCR (qRT-PCR) detected mRNA for the long AKAP9 isoforms and Yotiao, but the latter represented, on average, 2\% of the total AKAP9 message in HUVECs (Figure 1A). Given that the Yotiao protein was undetectable, the physiological relevance of the small pool of Yotiao message is unclear. Similar results were observed for adult HDMECs (data not shown). Thus, the long AKAP9 is the predominant isoform expressed in ECs. AKAP9 immunolocalized with GM130 (a cis-Golgi marker) and was present near the centrosomal marker \textgreek{gamma}-tubulin (Figure 1B). Immunohistochemical detection in human tissue revealed AKAP9 along with PECAM-1, an endothelial cell marker, in blood vessels and in the epidermal layer of normal human skin (Figure 1C).

To explore AKAP9 function, HUVECs were transfected with control siRNA or AKAP9 siRNA duplexes that targeted 5\’-terminal sequences present in AKAP9 and Yotiao mRNA. Silencing of AKAP9 was assessed by immunoblotting and corroborated by RT-PCR and immunofluorescence (Figure 1D). Depletion of AKAP9 in HUVECs had no effect on the localization of pericentrin, another centrosomal AKAP that is structurally related to AKAP9 (supplemental Figure 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article).

Statistical analysis

All data are presented as mean \( \pm \) SD except microtubule instantaneous growth rate and length of uninterrupted growth, for which median values are given. Two-sided paired \( t \) test or Wilcoxon paired rank test (for median values) were performed where appropriate. \( P < .05 \) was considered significant.

Results

Endothelial cells express the AKAP9 long isoforms and their silencing has no effect on cell division

AKAP9 protein expression was evaluated using an antibody that detects both the long AKAP9 and the Yotiao isoforms.\textsuperscript{27} Western blot analysis of HUVECs revealed a 400-kD AKAP9 species, while the 220-kD Yotiao was not observed (Figure 1A). Quantitative reverse transcriptase-PCR (qRT-PCR) detected mRNA for the long AKAP9 isoforms and Yotiao, but the latter represented, on average, 2\% of the total AKAP9 message in HUVECs (Figure 1A). Given that the Yotiao protein was undetectable, the physiological relevance of the small pool of Yotiao message is unclear. Similar results were observed for adult HDMECs (data not shown). Thus, the long AKAP9 is the predominant isoform expressed in ECs. AKAP9 immunolocalized with GM130 (a cis-Golgi marker) and was present near the centrosomal marker \textgreek{gamma}-tubulin (Figure 1B). Immunohistochemical detection in human tissue revealed AKAP9 along with PECAM-1, an endothelial cell marker, in blood vessels and in the epidermal layer of normal human skin (Figure 1C).

To explore AKAP9 function, HUVECs were transfected with control siRNA or AKAP9 siRNA duplexes that targeted 5\’-terminal sequences present in AKAP9 and Yotiao mRNA. Silencing of AKAP9 was assessed by immunoblotting and corroborated by RT-PCR and immunofluorescence (Figure 1D). Depletion of AKAP9 in HUVECs had no effect on the localization of pericentrin, another centrosomal AKAP that is structurally related to AKAP9 (supplemental Figure 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article).

Statistical analysis

All data are presented as mean \( \pm \) SD except microtubule instantaneous growth rate and length of uninterrupted growth, for which median values are given. Two-sided paired \( t \) test or Wilcoxon paired rank test (for median values) were performed where appropriate. \( P < .05 \) was considered significant.

Results

Endothelial cells express the AKAP9 long isoforms and their silencing has no effect on cell division

AKAP9 protein expression was evaluated using an antibody that detects both the long AKAP9 and the Yotiao isoforms.\textsuperscript{27} Western blot analysis of HUVECs revealed a 400-kD AKAP9 species, while the 220-kD Yotiao was not observed (Figure 1A). Quantitative reverse transcriptase-PCR (qRT-PCR) detected mRNA for the long AKAP9 isoforms and Yotiao, but the latter represented, on average, 2\% of the total AKAP9 message in HUVECs (Figure 1A). Given that the Yotiao protein was undetectable, the physiological relevance of the small pool of Yotiao message is unclear. Similar results were observed for adult HDMECs (data not shown). Thus, the long AKAP9 is the predominant isoform expressed in ECs. AKAP9 immunolocalized with GM130 (a cis-Golgi marker) and was present near the centrosomal marker \textgreek{gamma}-tubulin (Figure 1B). Immunohistochemical detection in human tissue revealed AKAP9 along with PECAM-1, an endothelial cell marker, in blood vessels and in the epidermal layer of normal human skin (Figure 1C).

To explore AKAP9 function, HUVECs were transfected with control siRNA or AKAP9 siRNA duplexes that targeted 5\’-terminal sequences present in AKAP9 and Yotiao mRNA. Silencing of AKAP9 was assessed by immunoblotting and corroborated by RT-PCR and immunofluorescence (Figure 1D). Depletion of AKAP9 in HUVECs had no effect on the localization of pericentrin, another centrosomal AKAP that is structurally related to AKAP9 (supplemental Figure 1, available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
AKAP9 depletion did not impair the ability of HUVECs to establish a confluent monolayer with the expected cobblestone morphology, nor did it alter the DNA profiles following cell-cycle analysis (Figure 1E).

**AKAP9 silencing impairs microtubule dynamics**

HUVECs transfected with control or AKAP9 siRNA were immunostained for α-tubulin and plus-end binding protein EB1. MTs organized a radial network in control siRNA-treated cells, while they formed a disordered meshwork in AKAP9-silenced cells. EB1 appeared as comet-like structures at microtubule tips in control siRNA-treated cells, as shown in other cell types. In contrast, EB1 appeared as dot-like structures in AKAP9-silenced cells despite EB1 accumulation at the centrosome and overall protein levels of EB1 that were comparable to control siRNA cells (Figure 2A). This suggests that depletion of AKAP9 might alter binding of EB1 to the growing microtubule ends or that it may inhibit microtubule polymerization.

We analyzed microtubule dynamics in AKAP9-depleted confluent HUVEC monolayers by live cell imaging (Figure 2). AKAP9 depletion resulted in a significant impairment of the instantaneous growth rate, a reduction of the microtubule growth length, and accumulation of active growing ends at the cell cortex compared with control siRNA cells, whereas the microtubule catastrophe frequency was not significantly increased (Figure 2B, supplemental Videos 1-2). Consistent with the latter observation, AKAP9 depletion did not affect microtubule turnover either at steady-state or following microtubule network recovery after nocodazole washout (Figure 2C), as assessed by probing cell lysates for detyrosination of α-tubulin (Glu-tubulin). Glu-tubulin is observed after microtubule assembly, and can be used as a marker for how long a microtubule has been assembled. In conclusion, AKAP9 regulates microtubule net polymerization in ECs by increasing the rate of growth while not significantly altering catastrophe events.

**AKAP9 is required for Epac-induced barrier properties**

We addressed the role of AKAP9 in cAMP-dependent regulation of endothelial barrier function. cAMP analogs have been extensively used to discriminate between the target proteins activated by cAMP elevation. We used a selective Epac activator, O-Me-cAMP, to assess the contribution of AKAP9 in Epac-induced enhancement of barrier properties. Measurement of the TER of the monolayers allowed a time-course analysis of endothelial barrier function. AKAP9 silencing had no effect on basal permeability in a confluent monolayer of HUVECs. While O-Me-cAMP treatment increased barrier properties in control siRNA ECs, AKAP9 siRNA cells failed to enhance TER in response to Epac activation. The enhancement of TER in response to S1P, an unrelated agonist, was similar in control and AKAP9-silenced monolayers, thus establishing specificity of AKAP9’s role in the cAMP/Epac-mediated pathways (Figure 3A shows cumulative data and supplemental Figure 2 shows raw data of a representative experiment). Similar TER results were obtained using a different AKAP9 siRNA sequence (data not shown). The role of AKAP9 was also confirmed in HDMECs (Figure 3B), which share with HUVECs many properties related to Epac and Rap activation. Permeability to macromolecules was assessed by measuring dextran (70-kDa) flux through the endothelial monolayer. As observed with TER, baseline permeability was similar in control and AKAP9 siRNA cells. O-Me-cAMP treatment prevented leakage in control siRNA HUVECs, while it failed to do so in AKAP9-depleted cells. The response to S1P was similar in control and AKAP9 siRNA cells (Figure 3C). Surprisingly, the PKA-selective cAMP analog N6-Benz-cAMP similarly enhanced barrier properties in both control and AKAP9 siRNA cells (supplemental Figure 2). In summary, AKAP9 is essential for Epac-mediated increase of endothelial barrier properties, while it is dispensable for maintaining barrier properties at steady-state, and for barrier enhancement in response to PKA activation and S1P.

**Figure 3. AKAP9-depleted cells display defects in Epac-induced enhancement of barrier properties.** (A) TER of AKAP9 (Akp9si) and control (Consi) siRNA-treated HUVEC monolayers at baseline and following the addition of O-Me-cAMP (left panel) or S1P (right panel) at the times indicated by arrows. N = 5 experiments. (B) TER in HDMECs in response to indicated agonists. N = 3 experiments. In panels A and B, TER measurement was normalized to the resistance of the sample at time 0, which was taken 10 minutes following the addition of siRNA duplexes. Data points are average ± SD. TER data points at 45 hours and greater reflect the effects of AKAP9 silencing on resistance. AKAP9 silencing did not significantly affect basal permeability in HUVECs (A) or HDMECs (B). However, AKAP9-silenced cells fail to respond to O-Me-cAMP. (C) Top panel, dextran leakage across control siRNA and AKAP9 siRNA cell monolayers after 15 minutes of treatment with vehicle control, O-Me, or S1P (n = 3). Bottom panels, time course of dextran leakage in control (left) and AKAP9-silenced (right) cells following agonist treatment for the indicated times in minutes. One of 2 representative experiments is shown; the data represent 2 determinations (in duplicate wells) at each time point. Results are reported as a percentage of the value obtained with control siRNA at the 15-minute time point, which was set at 100%. *P < .05.

From www.bloodjournal.org by guest on May 4, 2017. For personal use only.
Figure 4. AKAP9 associates with Epac1 and MTs and is required for the Epac-induced increase in microtubule growth rate. (A) Cosedimentation of AKAP9 and Epac1 with MTs. Cell lysates of 293 cells transfected with flag-tagged construct of AKAP9(2875-3899) fragment and full-length Epac1 were placed on ice to depolymerize the MTs. Samples were incubated with GTP and taxol at 37°C or held on ice (0°C) (negative control). After centrifugation, the pellet sample containing polymerized MTs (P) and supernatants (S) was separated by SDS-PAGE followed by immunoblot analysis. Anti-flag antibody was used to detect Epac1 and AKAP9 (top left panel), and anti-Epac1 antibody was used to specifically identify Epac1 (right panel). Bottom panels, anti-α-tubulin versus anti–actin antibody was used to specifically identify the microtubule-enriched compartment (ie, tubulin positive but actin negative). Only the pellet sample at 37°C (P; 37°C) containing polymerized MTs (lacking actin) was enriched in AKAP9 and Epac1 compared with the supernatant (S, 37°C). The lower-molecular-weight anti-flag-band was confirmed to be Epac1, because it was immunoreactive with the anti-Epac1 antibody (right panel). (B) Coimmunoprecipitation of AKAP9 and Epac1. 293T cells were transfected with Epac1-V5 and flag-empty vector alone or the indicated flag-AKAP9 fragments. Lysates (Input) were immunoprecipitated (IP) with IgG control or anti-flag antibody and probed for the presence of AKAP9 and Epac1 by immunoblotting (IB) with anti–flag (top panel) or anti-Epac1 (bottom panel) antibodies. Epac1 coimmunoprecipitated only with AKAP9(2875-3899) and AKAP9(1717-2876), and weakly with AKAP9(1229-1917). For panels A and B, 1 of 3 representative experiments is shown. (C) Microtubule regrowth following nocodazole-induced depolymerization. Control (Con) and AKAP9 siRNA (Akp9)–treated HUVECs were incubated with nocodazole on ice and microtubule regrowth was quantified 20 and 30 minutes after nocodazole washout in normal (-) or O-Me-cAMP (O-Me) (+) supplemented medium at 37°C. Cells were stained for α-tubulin and the length of the MTs was determined. *P < .05. n = 3 independent experiments.

AKAP9 complexes with Epac and promotes Epac-mediated net microtubule polymerization

The requirement of AKAP9 in Epac-induced endothelial barrier enhancement, together with previous reports suggesting an interaction of Epac6,11 and AKAP921 with MTs, predicted that these 2 proteins may interact in a complex with MTs. Immunofluorescence staining of HUVEC monolayers failed to show AKAP9 colocalization with peripheral MTs (data not shown). This interaction, previously observed in an epithelial cell line,21 may be transient in ECs or it may be dependent on cell-cycle or cAMP levels,3 as is the case for Epac.12,23 Therefore, a biochemical approach was pursued. Epac1 and a C-terminal AKAP9(2875-3899) fragment shown to have binding sites for MTs21 were transfected into HEK 293T cells and analyzed for their ability to interact with MTs in vitro. Both Epac1 and AKAP9 cosedimented with polymerized MTs (Figure 4A), suggesting that these proteins can interact with the microtubule lattice in cells. Whether AKAP9 and Epac1 formed a complex in cells was assessed by coimmunoprecipitation approaches using Epac1 and AKAP9 fragments. Epac1 coimmunoprecipitated with AKAP9(2875-3899) and AKAP9(1717-2876), and more weakly with AKAP9(1229-1917) (Figure 4B). Tubulin was not observed in the coimmunoprecipitated samples (data not shown), which could reflect suboptimal conditions for maintaining polymerized MTs because these samples were processed on ice.

A net increase in microtubule length has been observed in endothelial monolayers treated with O-Me-cAMP.11 In the present study, O-Me-cAMP was also shown to increase the net microtubule polymerization in control siRNA-treated cells during microtubule regrowth (Figure 4C), but failed to do so in AKAP9 siRNA-treated cells (Figure 4C) despite normal expression of Epac1 in these cells (supplemental Figure 3). Although O-Me-cAMP–mediated microtubule growth does not require active Rap GTPases,11 it was, as expected, Epac dependent because silencing of Epac1 attenuated this process (supplemental Figure 3). These data suggest that Epac exerts its effect on MTs through an AKAP9-dependent pathway that does not require active Rap GTPases.

AKAP9 is not required for Epac activation of Rap GTPases, reorganization of cortical actin, or de novo VE-cadherin adhesion

To explore the mechanisms underlying the role of AKAP9 in Epac-induced barrier function, we examined whether AKAP9 was required for Epac-induced Rap activation and cortical actin and VE-cadherin homophilic interactions. After O-Me-cAMP, GTP loading of Rap GTPase in control and AKAP9 siRNA-treated cells was indistinguishable (Figure 5A). Moreover, O-Me-cAMP–induced Epac activation led to a comparable increase in cortical actin bundles and junctional VE-cadherin linearity in control and AKAP9-silenced cells (Figure 5B). Consistent with the latter observation, control and AKAP9 siRNA-treated cells similarly adhered to plate-immobilized VE-cadherin and augmented their adhesion upon stimulation with O-Me-cAMP (Figure 5C). Thus, AKAP9 is not required for the formation and maintenance of VE-cadherin homophilic interactions. To address the role of
AKAP9 in de novo assembly of VE-cadherin adhesion at AJs, we pursued a Ca\(^{2+}\) switch strategy. ECs cultured in the presence of EGTA lose Ca\(^{2+}\)-dependent, homotypic interactions of junctional VE-cadherin and associated proteins, while subsequent Ca\(^{2+}\) replenishment reverses this process.\(^{34}\) Ca\(^{2+}\) depletion induced disassembly of VE-cadherin adhesion and Ca\(^{2+}\) repletion led to reappearance of VE-cadherin and its associated catenins at cell-cell contacts in both control and AKAP9-silenced monolayers (Figure 5D). In addition to catenins, the minus-end-directed microtubule motor protein dynein, which is known to associate with a AKAP9-binding partner, dynactin,\(^{21}\) interacts with β-catenin at the AJs of epithelial cells to capture microtubule plus ends and to facilitate the formation of nascent junctions.\(^{35}\) Dynein was not observed at cell-cell contacts of resting, confluent ECs, but was rapidly and transiently localized to AJs following Ca\(^{2+}\) switch in both control and AKAP9 siRNA cells (Figure 5E).

In summary, AKAP9 is not essential for relaying Epac effects on Rap GTase activation and the accompanying changes in the organization of cortical actin, or for VE-cadherin homophilic adhesion and localization of VE-cadherin and associated catenins and dynactin at junctions.

AKAP9-mediated adhesion of integrins contributes to Epac-induced enhancement of barrier properties

Given the absence of changes in VE-cadherin homophilic interactions in AKAP9-silenced cells, we explored the possibility that AKAP9 promotes Epac-induced barrier properties by supporting integrin-mediated adhesion. AKAP9 silencing led to a significant defect in the ability of suspended cells to adhere to immobilized RGD peptide compared with control siRNA cells (Figure 6A), despite similar integrin cell surface expression in both groups (Figure 6B). Although O-Me-cAMP was shown to increase integrin adhesion to RGD in an ovarian carcinoma cell line,\(^{36}\) it did not enhance endothelial cell adhesion to RGD (data not shown). Epac1 silencing did reduce their ability to bind RGD (Figure 6A), indicating that endogenous Epac1 activity promotes integrin-mediated adhesion. Interestingly, Epac1 siRNA resulted in a significant change in the organization of actin in the cells that did adhere to RGD compared with adherent control siRNA and AKAP9 siRNA cells (Figure 6A). These data support the model that, while the Epac/AKAP9 axis is not essential for cortical actin reorganization, Epac activation of Rap likely drives this process.

The contribution of RGD integrins specifically to the Epac-induced increase in barrier properties was evaluated. Prolonged treatment with soluble RGD peptide increased permeability in HUVECs plated on either fibronectin or collagen type IV. Pretreatment with RGD peptide for 1 hour had no effect on baseline permeability but significantly impaired O-Me-cAMP–induced enhancement of barrier function on both matrices (Figure 6C). To identify the RGD integrins involved, we evaluated the effect of functional blocking antibodies to α\(_5\) and α\(_\text{v}\) previously identified at cell-cell contacts,\(^4\) on barrier function. Unexpectedly, functional
blocking antibody to \(\alpha_v\) only effectively inhibited O-Me-cAMP effects on cells plated on fibronectin, while \(\alpha_5\) antibody had a marked effect only on cells cultured on collagen (Figure 6D). The differential effects of the blocking antibodies prompted us to examine the distribution of integrins on cells adherent to fibronectin and collagen. \(\alpha_v\) immunolocalized to cell-cell contacts of cells plated on fibronectin, but not collagen, and its levels increased following O-Me-cAMP treatment (Figure 6E). \(\alpha_5\) was absent at the borders of cells adherent to either collagen or fibronectin, but upon O-Me-cAMP treatment, appeared only at junctions of cells plated on collagen (Figure 6E). Thus, O-Me-cAMP increases the accumulation of \(\alpha_v\) at cell-cell contacts of cells adherent to fibronectin and redistributes \(\alpha_5\) to junctions in cells plated on collagen. The correlation between a particular integrin at the junctions and its role in O-Me-cAMP–induced barrier function infers that integrins at cell-cell contacts play primary roles in enhancing barrier properties following Epac activation. We were unable to determine the effect of AKAP9 silencing on integrin redistribution following O-Me-cAMP treatment, because the electroporation technique to introduce siRNA resulted in the loss of detectability of integrins at lateral borders. However, we propose that integrins did contribute to barrier function even under these conditions, because RGD inhibited barrier enhancement by O-Me-cAMP in control siRNA cells (data not shown).

Discussion

Our results describe a role for AKAP9 in regulating microtubule dynamics and enhancing endothelial barrier downstream of Epac activation. Whereas AKAP9 is required for persistent microtubule growth under steady-state conditions, it was found not to be essential for maintaining basal barrier properties. Instead, it was required when the cell was challenged to make new adhesive contacts, as is the case when Epac activation promotes adhesion at cell-cell contacts to enhance barrier function. Collectively, these findings are important for several reasons. First, they uncover new biological roles for AKAP9 that appear distinct from those of Yotiao, the well-described shorter AKAP9 isoform. Yotiao, present at the plasma membrane, interacts with the N-methyl D-aspartate receptor to modulate its activity at synapses and with a cardiac potassium channel to regulate the repolarization of the heart.14,27 Second, because AKAP9 silencing affected microtubule growth, it allowed us to link microtubule dynamics to specific endothelial cell responses. Third, the data provide compelling genetic
For other junctional processes affecting endothelial barrier properties and microtubule dynamics in AKAP9-silenced cells has consequences of the absence of AKAP9. It remains possible that perturbation of microtubule capture at junctions distribute normally in the relative cortical actin and receptor complexes potentially required for homophilic adhesion.

These data support the conclusion that 

H9252α-catenin at nascent junctions, nor was it essential for VE-cadherin also not required for the localization of VE-cadherin, p120, and show that dynein transiently appeared at newly forming junctions actin cytoskeleton.41 Dynein also interacts with AKAP9.21 We depolymerizing, microtubule ends.39 Furthermore, conclusive roles because EB1 is associated with growing, but not pausing or depolymerizing, microtubule ends.39

Further, conclusive roles for AKAP9 in the microtubule polymerization rate, a specific aspect of microtubule dynamics, was obtained by live-cell imaging. Despite the change in microtubule growth in AKAP9-silenced cells, the stability of MTs, which is promoted by their capture at the cell cortex,40 was unaffected. In epithelial cells, dynein (a minus-end-directed microtubule motor protein) associates with β-catenin at AJs and binds microtubule +TIPs to facilitate the delivery of junctional components,12 and its localization requires an intact actin cytoskeleton.41 Dynein also interacts with AKAP9.21

We show that dynein transiently appeared at newly forming junctions of ECs, and that this was not dependent on AKAP9. AKAP9 was also not required for the localization of VE-cadherin, p120, and β-catenin at nascent junctions, nor was it essential for VE-cadherin homophilic adhesion. These data support the conclusion that cortical actin and receptor complexes potentially required for microtubule capture at junctions distribute normally in the relative absence of AKAP9. It remains possible that perturbation of microtubule dynamics in AKAP9-silenced cells has consequences for other junctional processes affecting endothelial barrier properties that were not directly measured in our study.

The contribution of AKAP9 in the Epac-mediated increase in barrier properties and microtubule regrowth was tricky. Our biochemical communoprecipitation approach suggests that, like PKA, Epac can potentially interact with AKAP9 through multiple sites. The interaction(s) could be direct or facilitated via intermediate binding partners such as protein phosphatase 2A and PDE4D3, both of which bind both AKAP9,19 and Epac,6,44 and both of which have binding sites in the AKAP9 fragments that communoprecipitate Epac1. The possibility also exists that AKAP9-mediated microtubule growth delivers active Epac to specific locations, which does not have a priori require AKAP9 and Epac1 to be in a complex. Under conditions of AKAP9 depletion that resulted in defects in Epac-induced enhancement of barrier properties, there was a surprising lack of effect on Epac-induced Rap activation.

Because it is well-accepted that Rap is required for Epac-induced enhancement of barrier function, we propose that Epac in complex with AKAP9 promotes microtubule growth, thus creating tracks for delivery of Rap effectors to AJs, where Rap is localized.26,45 Thus, although Rap activation per se does not require AKAP9, the effectors of Rap likely require AKAP9 to promote junction strengthening (Figure 7).

The absence of Epac9 silencing on Epac-induced VE-cadherin homophilic adhesion and localization left unanswered the question of how the Epac/AKAP9 axis regulates barrier properties. In a stable, mature endothelial monolayer, functional blockade of paxillin or the RGD-binding integrins increases vascular permeability,3,4,46 and RGD peptides induce vascular permeability in vivo.3 AKAP9 was required for de novo integrin-mediated adhesion. Epac1 silencing also resulted in a reduction in integrin-mediated adhesion, but it remains a possibility that AKAP9 affects additional integrin-dependent functions that are independent of Epac activity. The requirement for RGD-binding integrin α5 versus α5 in O-Me-cAMP-induced barrier properties was coincident with the presence of that integrin at cell-cell contacts, thus supporting the argument that the junctional pool of integrins contributes to barrier enhancement. The mechanism for differential integrin localization that is dependent on the substratum is not clear, but we reason that on fibronectin, α5, the principal fibronectin-binding integrin, is sequestered primarily at cell-matrix sites, while αv, which has a much lower affinity for fibronectin than αvβ3,47 preferentially localizes to the cell-cell border. Conversely, on collagen, αv binds collagen48 at the abluminal surface and αv is enriched at the cell-cell interface. The ligand(s) at the cell-cell border for RGD-binding integrins are likely extracellular matrix proteins such as fibronectin, laminin, and collagen type IV, which are produced by the endothelium and concentrated at lateral cell-cell contacts.4 Previously work suggests that vascular endothelial growth factor (VEGF)–induced permeability is also dependent on integrins,49 whereas in our case, integrins increased barrier function. One possible explanation for this is that VE-cadherin recycling in resting monolayers is regulated by integrins and that this parameter is differentially influenced by VEGF and Epac.
VE-cadherin and integrins likely play codominant roles in junctional remodeling, because their functions are not mutually exclusive.\(^{50}\) We propose that Epac activation of Rap at junctions enhances cortical actin, which drives VE-cadherin homophilic interactions and assembly of cortical complexes. The assembled complexes capture MTs, the persistent growth of which is dependent on Epac/AKAP9 activity. These MTs may deliver factors such as the Rap effectors RapL and KRIT-1, which bind MTs\(^{51-53}\) and regulate integrins\(^{54}\) to promote integrin function at AJs (Figure 7).

In conclusion, AKAP9 is a central player in microtubule dynamics in human ECs that is linked to the ability of the endothelial monolayer to regulate its barrier properties in response to cAMP-mediated Epac1 activation. AKAP9 is required for integrin-mediated adhesion, and this property at cell-cell contacts contributes to the Epac1-induced enhancement of barrier function. Our studies suggest that AKAP9 may be important in relaying other Epac-regulated cellular responses, from insulin secretion and neurotransmitter release to leukocyte activation and cardiac contraction.\(^{9}\) Identifying the contribution of AKAP9, a member of the AKAP family of proteins that are known to temporally and spatially compartmentalize cAMP-induced signals, to specific Epac functions may help to explain how Epac fulfills its diverse roles within a single cell.

Acknowledgments

We thank George Stavrakis in the Morphology Support Core facility for immunostaining of tissue. We are grateful to Drs Lei Chen and Robert Kass (Columbia University, New York, NY) for anti-AKAP9 antibody, to Dr Kerry S. Campbell (Fox Chase Cancer Center, Philadelphia, PA) for anti-dynein light chain antibody, and to Dr G. G. Gunderson (Columbia University) for antibody against Glu-tubulin. We thank Dr Andrew P. Kowalczyk (Emory University, Atlanta, GA) for the kind gift of HDMEC. We thank Drs Francis W. Lucsinskas and Andrew Lichtman for valuable discussions.

This work was supported by the National Institutes of Health, PO1HL036028 and RO1 DK51643 (to T.M.), KO1 AR054984 (to X.C.) and by a scholarship from the Norvartis Foundation (formerly Ciba-Geigy-Jubilee Foundation; to T.E.).

Authorship

Contribution: S.S., T.E., and X.C. designed and performed the research, analyzed the data, and made the figures; Y.K. aided in the analysis and interpretation of the data; M.T. and Y.O. provided valuable reagents; T.N.M. designed the research, analyzed the data, and wrote the paper; and S.S., T.E., X.C., and Y.K. revised the paper for important intellectual content.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Tanya N. Mayadas, Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur NR 7520, Boston, MA 02115; e-mail: tmayadas@rics.bwh.harvard.edu.

References

7. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Geuze HJ. Redistribution of Glu-tubulin. We thank Dr Andrew P. Kowalczyk (Emory University, Atlanta, GA) for the kind gift of HDMEC. We thank Drs Francis W. Lucsinskas and Andrew Lichtman for valuable discussions.

This work was supported by the National Institutes of Health, PO1HL036028 and RO1 DK51643 (to T.M.), KO1 AR054984 (to X.C.) and by a scholarship from the Norvartis Foundation (formerly Ciba-Geigy-Jubilee Foundation; to T.E.).

Authorship

Contribution: S.S., T.E., and X.C. designed and performed the research, analyzed the data, and made the figures; Y.K. aided in the analysis and interpretation of the data; M.T. and Y.O. provided valuable reagents; T.N.M. designed the research, analyzed the data, and wrote the paper; and S.S., T.E., X.C., and Y.K. revised the paper for important intellectual content.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Tanya N. Mayadas, Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur NR 7520, Boston, MA 02115; e-mail: tmayadas@rics.bwh.harvard.edu.

References

7. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Geuze HJ. Redistribution of Glu-tubulin. We thank Dr Andrew P. Kowalczyk (Emory University, Atlanta, GA) for the kind gift of HDMEC. We thank Drs Francis W. Lucsinskas and Andrew Lichtman for valuable discussions.

This work was supported by the National Institutes of Health, PO1HL036028 and RO1 DK51643 (to T.M.), KO1 AR054984 (to X.C.) and by a scholarship from the Norvartis Foundation (formerly Ciba-Geigy-Jubilee Foundation; to T.E.).

Authorship

Contribution: S.S., T.E., and X.C. designed and performed the research, analyzed the data, and made the figures; Y.K. aided in the analysis and interpretation of the data; M.T. and Y.O. provided valuable reagents; T.N.M. designed the research, analyzed the data, and wrote the paper; and S.S., T.E., X.C., and Y.K. revised the paper for important intellectual content.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Tanya N. Mayadas, Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur NR 7520, Boston, MA 02115; e-mail: tmayadas@rics.bwh.harvard.edu.

References

7. Nijholt IM, Dolga AM, Ostroveanu A, Luiten PG, Geuze HJ. Redistribution of Glu-tubulin. We thank Dr Andrew P. Kowalczyk (Emory University, Atlanta, GA) for the kind gift of HDMEC. We thank Drs Francis W. Lucsinskas and Andrew Lichtman for valuable discussions.

This work was supported by the National Institutes of Health, PO1HL036028 and RO1 DK51643 (to T.M.), KO1 AR054984 (to X.C.) and by a scholarship from the Norvartis Foundation (formerly Ciba-Geigy-Jubilee Foundation; to T.E.).

Authorship

Contribution: S.S., T.E., and X.C. designed and performed the research, analyzed the data, and made the figures; Y.K. aided in the analysis and interpretation of the data; M.T. and Y.O. provided valuable reagents; T.N.M. designed the research, analyzed the data, and wrote the paper; and S.S., T.E., X.C., and Y.K. revised the paper for important intellectual content.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Tanya N. Mayadas, Professor of Pathology, Brigham and Women’s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur NR 7520, Boston, MA 02115; e-mail: tmayadas@rics.bwh.harvard.edu.


39. Morrison EE, Wardlewth BN, Askham JM, Markham AF, Meredith DM, EB1, a protein which interacts with the APC tumour suppressor, is associated with the microtubule cytoskeleton throughout the cell cycle. Oncogene. 1998; 17(26):3471-3477.


AKAP9 regulation of microtubule dynamics promotes Epac1-induced endothelial barrier properties

Seema Sehrawat, Thomas Ernandez, Xavier Cullere, Mikiko Takahashi, Yoshitaka Ono, Yulia Komarova and Tanya N. Mayadas